ArticleMicrobial biotechnology2026
Efficient Extracellular Production of Insulin Glargine in Trichoderma reesei by an Integrative Secretion-Based Strategy.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Insulin glargine, a long-acting insulin analog, is essential for diabetes treatment. However, its industrial production remains challenging due to limitations in conventional expression systems. Here, we employed the industrial filamentous fungus Trichoderma reesei as an alternative expression host for insulin glargine production, leveraging its superior protein secretion capacity. Initially, expression constructs containing the constitutive Pcdna1 promoter and CBH1 signal peptide (SP1) showed successful transcription but failed to achieve extracellular secretion, presumably due to induced endoplasmic reticulum (ER) stress. Consequently, we implemented a fusion protein strategy utilising three distinct carrier proteins (CBH1, CBH2, and LA-20) to enhance glargine secretion. Notably, the CBH1 fusion not only enabled detectable glargine secretion but also significantly alleviated the ER stress. Furthermore, replacement of SP1 with the Aspergillus niger β-glucoamylase signal peptide achieved a fourfold enhancement in glargine secretion and further reduced cellular stress responses. Following these systematic optimizations, a final yield of 58.95 mIU/L glargine was achieved in shake-flask cultures. Thus, the combined strategy described here could achieve extracellular production of glargine in T. reesei, suggesting that it is a promising host for secretory production of therapeutic recombinant proteins, particularly complex analogs like glargine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.